Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2012 Scrip 100: Survival of the fittest

This article was originally published in Scrip

Executive Summary

It’s finally here. For a while, a dark cloud has been looming ominously over the industry and, on this occasion, when it rains, it pours. Billions of dollars in revenues are set to be washed away from the P&L sheets of leading pharmaceutical companies as some of their most prized assets, their blockbuster drugs, suffer the consequences of patent expiry.

You may also be interested in...



2012 Scrip Asia 100 - Japan expands global footprint

Japan’s pharmaceutical industry is in the midst of a defining period. The sector has evolved dramatically over the past decade, as companies attempt to gain ground on their western peers in meeting the demands of global healthcare markets. While the top ten companies in Japan pharma are dominant within their domestic market, generating more than half of overall prescription pharma revenues in Japan, a range of factors have provided the impetus for companies to expand their global footprint.

Nycomed acquisition by Takeda would boost global footprint

While neither Takeda Pharmaceutical nor Nycomed have confirmed that they might be engaged in takeover talks, the continued strength of the Japanese Yen in the global economy, fast-approaching generic pressures and a strong strategic rationale all contribute to the validity of this rumored deal. And at a price mooted at between $10bn and $12bn, such a transaction would be the largest acquisition in Takeda's history, surpassing its $8.8 billion purchase of Millennium.

2011 Scrip 100: Why the smart money is on injectables

Topics

Related Companies

UsernamePublicRestriction

Register

CO008261

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel